… Treating patients with ALKrearranged non-small-cell lung cancer: mechanisms of resistance
… Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (…

… in patients with advanced ALK-rearranged non-small-cell lung … activity with ceritinib in
patients with ALKrearranged … Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with …

… is one of the most lethal malignancies in the world, with non-small cell lung cancer (NSCLC) …
summarizing the efficacy and safety of ALK inhibitors in treating NSCLC brain metastases. …

… Non-small cell lung cancer (NSCLC) is the most common histological type of … 中患者每日
口服alectinib两次 [29, 30] 。Ⅰ期试验纳入的24例患者每日口服20 mg-300 mg的alectinib两次。在…

… ALK基因重排在非小细胞肺癌（non-small cell lung cancer, NSCLC）中发生率约3%-5%。ALK基因…
450 mg/d Ceritinib的15个月无进展生存率估计值较750 mg/d Ceritinib高，这为临床不能耐受…

… a common driver gene of non-small cell lung cancer (NSCLC). Ceritinib is a second-generation …
Therefore, this study intends to investigate the safety and preliminary efficacy of ceritinib …

… rate worldwide, and non-small cell lung cancer (NSCLC) … potency on inhibiting ALK activity
and controlling brain metastases … 然而二代药物各自的敏感位点不尽相同，塞瑞替尼（Ceritinib）…

… kinase and its rearrangements occur in non-small cell lung cancer (NSCLC), resulting in …
treatments and an addition of options in ALK-rearranged NSCLC. Pulmonary toxicity is one …

… Safety and activity of alectinib against systemic disease and brain metastases in patients
with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG):results from the …